Primary central nervous system tumors: Advances in knowledge and treatment

Ca-A Cancer Journal for Clinicians

Volumn 48, Issue 6, 1998, Pages 331-360

  Prados, Michael D ^a   Berger, Mitchell S ^a   Wilson, Charles B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; NIMUSTINE; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; PROCARBAZINE; PROTEIN KINASE C; TAMOXIFEN; TENIPOSIDE; TOPOTECAN; VASCULOTROPIN; VINCRISTINE;

ANGIOGENESIS; ARTICLE; ASTROCYTOMA; BLOOD BRAIN BARRIER; BRACHYTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM TUMOR; COMPUTER ASSISTED TOMOGRAPHY; EPENDYMOMA; GLIOBLASTOMA; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAGNETIC RESONANCE ANGIOGRAPHY; MEDULLOBLASTOMA; MENINGIOMA; MOLECULAR BIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOSURGERY; STEREOTAXIC SURGERY; TUMOR CLASSIFICATION;

EID: 0031735869     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.48.6.331     Document Type: Article

References (47)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
2. Kleihues P, Burger PC, Scheithauer BW: The new WHO classification of brain tumours. Brain Pathol 1993;3:255-268.
3. Daumas-Duport C, Scheithauer B, O'Fallon J, et al: Grading of astrocytomas: A simple and reproducible method. Cancer 1988;62:2152-2165.
4. Bogler O, Huang HJ, Kleihues P, et al: The p53 gene and its role in human brain tumors. Glia 1995;15:308-327.
5. Bigner SH, Humphrey PA, Wong AJ, et al: Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990;50:8017-8022.
6. Westermark B, Heldin CH, Nister M: Platelet-derived growth factor in human glioma. Glia 1995;15:257-263.
7. Morgan DO: Principles of CDK regulation. Nature 1995;374:131-134.
8. Buchkovich K, Duffy LA, Harlow E: The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 1989;58:1097-1105.
9. Elledge SJ, Harper JW: CDK inhibitors: On the threshold of checkpoints and development. Curr Opin Cell Biol 1993;6:847-852.
10. Pilkington GJ: Tumour cell migration in the central nervous system. Brain Pathol 1994;4:157-166.
11. Cheng SY, Huang HJ, Nagane M, et al: Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 1996;93:8502-8507.
12. Seizinger BR, Rouleau GA, Ozelius LJ, et al: Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell 1987;49:589-594.
13. Rouleau GA, Merel P, Lutchman M, et al: Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363:515-521.
14. Latif F, Tory K, Gnarra J, et al: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-1320.
15. Carbonara C, Longa L, Grosso E, et al: Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas. Genes Chromosomes Cancer 1996;15:18-25.
16. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al: A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358-5362.
17. Valk PE, Budinger TF, Levin VA, et al: PET of malignant cerebral tumors after interstitial brachytherapy: Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg 1988;69:830-838.
18. Taylor JS, Langston JW, Reddick WE, et al: Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. Int J Radiat Oncol Biol Phys 1996;36:1251-1261.
19. McDermott MW, Gutin PH, Larson DA, et al: Interstitial brachytherapy. Neurosure Clin N Am 1990;1:801-824.
20. 125I brachytherapy for recurrent high-grade astrocytomas. Im J Radiat Oncol Biol Phys 1996;35:541-547.
21. Leksell L: The stereotactic method and radiosurgery of the brain. Acta Chir Scand 1951;102:316-319.
22. Larson DA, Flickinger JC, Loeffler JS: Stereotactic radiosurgery: Techniques and results, in De Vita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology Updates. Philadelphia, JB Lippincott; 1993, pp 1-19.
23. 6-alkylguanine-DNA alkyltransferase activity in human brain and brain tumors. Carcinogenesis 1984;5:321-124.
24. Green SB, Byar DP, Walker MD, et al: Comparisons of carmustine, procarbazine and high-dose methylprednisone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treatment Reports 1983;67:121-132.
25. Shapiro WR, Green SB, Burger PC, et al: Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma: Brain Tumor Cooperative Group Trial 8001. J Neurosurg 1989;71:1-9.
26. Fine HA, Dear KB, Loeffler JS, et al: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-2597.
27. Levin VA, Prados MD, Wara WM, et al: Radiation therapy and bromodeoxyuridine followed by procarbazine, lomustine, and vincristine chemotherapy for the treatment of anaplastic gliomas. Int J Radial Oncol Biol Phys 1995;32:75-83.
28. Prados MD, Gutin PH, Phillips TL, et al: Highly anaplastic astrocytoma: A review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys 1992;23:3-8.
29. Levin VA, Silver P, Hannigan J, et al: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 1990;18:321-324.
30. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988;23:360-364.
31. Packer RJ, Lange B, Ater J, et al: Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 1993;11:850-856.
32. Shaw EG, Daumas-Duport C, Scheithauer BW, et al: Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 1989;70:853-861.
33. Philippen JH, Clemenceau SH, Fauchon FH, et al: Supratentorial low-grade astrocytomas in adults. Neurosurgery 1993;32:554-559.
34. Soffietti R, Chio A, Giordana MT, et al: Prognostic factors in well-differentiated cerebral astrocytomas in the adult. Neurosurgery 1989;24:686-692.
35. Berger MS, Deliganis AV, Dobbins J, et al: The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 1994;74:1784-1791.
36. Karim AB, Maat B, Hatlevoll R, et al: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 1996;36:549-556.
37. Shaw EG, Evans RG, Scheithauer BW, et al: Postoperative radiotherapy of intracranial ependymoma in pediatric and adult patients. Int J Radiat Oncol Biol Phys 1987;13:1457-1462.
38. Sutton LN, Goldwein J, Perilongo G, et al: Prognostic factors in childhood ependymomas. Pediatr Neurosurg 1990;16:57-65.
39. Vanuytsel L, Brada M: The role of prophylactic spinal irradiation in localized intracranial ependymoma. Int J Radiat Oncol Biol Phys 1991;21:825-830.
40. Tait DM, Thornton-Jones H, Bloom HJ, et al: Adjuvant chemotherapy for medulloblastoma: The first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990;26:464-469.
41. Evans AE, Jenkins RD, Sposto R, et al: The treatment of medulloblastoma: Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990;72:572-582.
42. Lefkowitz IB, Packer RJ, Siegel KR, et al: Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine. Cancer 1990;65:412-417.
43. Louis DN, Ramesh V, Gusella JF: Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors. Brain Pathol 1995;5:163-172.
44. Simpson D: The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957;20:22-39.
45. Black PM, Loeffler JS (eds): Cancer of the Nervous System. Cambridge, MA, Blackwell Science, 1997.
46. Youmans JR (ed): Neurological Surgery: A Comprehensive Reference Guide to the Diagnosis and Management of Neurosurgical Problems, ed 4. Philadelphia, WB Saunders, 1996, pp 2493-3187.
47. Kaye AH, Laws ER Jr (eds): Brain Tumors: An Encyclopedic Approach. New York, Churchill Livingstone, 1995.